Interestingly, galactolysis has been recently suggested as the prospective therapeutic target for hepatocellular carcinoma, based on inhibition of galactokinase (GALK) or galactose-1 phosphate uridylyltransferase (GALT) (40). The gene discussed is GALT; the disease is hepatocellular carcinoma.